ATE522502T1 - Therapeutisches mittel gegen atemwegserkrankungen,das ein 4-hydroxypiperidinderivat als wirkstoff enthält - Google Patents
Therapeutisches mittel gegen atemwegserkrankungen,das ein 4-hydroxypiperidinderivat als wirkstoff enthältInfo
- Publication number
- ATE522502T1 ATE522502T1 AT03811921T AT03811921T ATE522502T1 AT E522502 T1 ATE522502 T1 AT E522502T1 AT 03811921 T AT03811921 T AT 03811921T AT 03811921 T AT03811921 T AT 03811921T AT E522502 T1 ATE522502 T1 AT E522502T1
- Authority
- AT
- Austria
- Prior art keywords
- halogenated
- hydrogen
- respiratory diseases
- lower alkyl
- active ingredient
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical class OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- -1 (substituted) benzylidene Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 206010006451 bronchitis Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 208000023504 respiratory system disease Diseases 0.000 abstract 2
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 230000000954 anitussive effect Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 201000009240 nasopharyngitis Diseases 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002341251 | 2002-11-25 | ||
| PCT/JP2003/015005 WO2004048326A1 (ja) | 2002-11-25 | 2003-11-25 | ４−ヒドロキシピペリジン誘導体を有効成分とする呼吸器疾患治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE522502T1 true ATE522502T1 (de) | 2011-09-15 |
Family
ID=32375845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03811921T ATE522502T1 (de) | 2002-11-25 | 2003-11-25 | Therapeutisches mittel gegen atemwegserkrankungen,das ein 4-hydroxypiperidinderivat als wirkstoff enthält |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7494987B2 (de) |
| EP (1) | EP1568688B1 (de) |
| JP (1) | JP4544999B2 (de) |
| AT (1) | ATE522502T1 (de) |
| AU (1) | AU2003302416A1 (de) |
| CA (1) | CA2507509A1 (de) |
| WO (1) | WO2004048326A1 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008179541A (ja) * | 2005-05-02 | 2008-08-07 | Mochida Pharmaceut Co Ltd | 神経因性疼痛治療薬 |
| AU2007203969B2 (en) * | 2006-01-04 | 2012-04-05 | Cipla Limited | Process and intermediate for preparation of donepezil |
| AR065816A1 (es) * | 2007-03-26 | 2009-07-01 | Theramex | Regimen anticonceptivo oral |
| CN104945420A (zh) | 2009-06-29 | 2015-09-30 | 因塞特公司 | 作为pi3k抑制剂的嘧啶酮类 |
| WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| TWI487697B (zh) * | 2009-12-23 | 2015-06-11 | Palau Pharma Sa | 作為組織胺ｈ受體拮抗劑之胺基烷基嘧啶衍生物類 |
| AR081823A1 (es) | 2010-04-14 | 2012-10-24 | Incyte Corp | DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd |
| EP2655374B1 (de) | 2010-12-20 | 2019-10-23 | Incyte Holdings Corporation | N-(1-(substituierte phenyl)ethyl)-9h-purin-6-amine als pi3k-hemmer |
| US9108984B2 (en) * | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| WO2012135009A1 (en) * | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| KR102507287B1 (ko) | 2011-09-02 | 2023-03-07 | 인사이트 홀딩스 코포레이션 | Ｐｉ３ｋ 억제제로서 헤테로시클릴아민 |
| CN106117194A (zh) * | 2011-12-27 | 2016-11-16 | 铁木医药有限公司 | 可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类 |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| US8969365B2 (en) | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
| US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| KR20170055531A (ko) * | 2014-09-17 | 2017-05-19 | 아이언우드 파마슈티컬스, 인코포레이티드 | 에스지씨 자극제 |
| SI3831833T1 (sl) | 2015-02-27 | 2023-03-31 | Incyte Holdings Corporation | Postopki za pripravo inhibitorja PI3K |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| CA3101323A1 (en) | 2018-06-01 | 2019-12-05 | Incyte Corporation | Dosing regimen for the treatment of pi3k related disorders |
| CN115215787A (zh) * | 2021-04-19 | 2022-10-21 | 中国科学院上海药物研究所 | 生长抑素受体5拮抗剂及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4508724A (en) * | 1984-02-03 | 1985-04-02 | A. H. Robins Company, Inc. | Aryloxymethylpyrrolidinols and piperidinols having antidepressant, antiarrhythmic or hypotensive activity |
| MY104343A (en) * | 1987-11-23 | 1994-03-31 | Janssen Pharmaceutica Nv | Novel pyridizinamine deravatives |
| JP2571904B2 (ja) | 1991-07-17 | 1997-01-16 | フアイザー・インコーポレイテツド | 抗虚血剤としての２−（４−ヒドロキシピペリジノ）−１−アルカノール誘導体 |
| US5696267A (en) | 1995-05-02 | 1997-12-09 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| KR20000052856A (ko) | 1996-10-28 | 2000-08-25 | 둘락 노먼 씨. | 뉴로키닌 길항제로서의 치환된 아릴알킬아민 |
| ID29137A (id) | 1998-07-27 | 2001-08-02 | Schering Corp | Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1 |
| JP2000103782A (ja) | 1998-07-31 | 2000-04-11 | Kyorin Pharmaceut Co Ltd | 環状アミン誘導体及びその製造方法 |
| EP1182193A4 (de) | 1999-04-09 | 2002-09-11 | Mochida Pharm Co Ltd | Medikamente gegen neuropathische schmerzen |
| WO2000061557A1 (en) | 1999-04-09 | 2000-10-19 | Mochida Pharmaceutical Co., Ltd. | 4-hydroxypiperidine derivatives having antiarrhythmic effect |
| CA2422055A1 (en) | 2000-09-11 | 2002-03-21 | Sepracor, Inc. | Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| JP2005097120A (ja) * | 2000-10-06 | 2005-04-14 | Mochida Pharmaceut Co Ltd | ４−ヒドロキシピペリジン誘導体の非潮解性塩 |
| WO2002096875A1 (fr) | 2001-05-25 | 2002-12-05 | Mochida Pharmaceutical Co., Ltd. | Derive de 4-hydroxypiperidine a activite analgesique |
-
2003
- 2003-11-25 JP JP2004555031A patent/JP4544999B2/ja not_active Expired - Fee Related
- 2003-11-25 CA CA002507509A patent/CA2507509A1/en not_active Abandoned
- 2003-11-25 AU AU2003302416A patent/AU2003302416A1/en not_active Abandoned
- 2003-11-25 EP EP03811921A patent/EP1568688B1/de not_active Expired - Lifetime
- 2003-11-25 US US10/536,459 patent/US7494987B2/en not_active Expired - Fee Related
- 2003-11-25 WO PCT/JP2003/015005 patent/WO2004048326A1/ja not_active Ceased
- 2003-11-25 AT AT03811921T patent/ATE522502T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004048326A1 (ja) | 2004-06-10 |
| CA2507509A1 (en) | 2004-06-10 |
| JPWO2004048326A1 (ja) | 2006-03-23 |
| EP1568688B1 (de) | 2011-08-31 |
| AU2003302416A1 (en) | 2004-06-18 |
| EP1568688A1 (de) | 2005-08-31 |
| US7494987B2 (en) | 2009-02-24 |
| EP1568688A4 (de) | 2008-12-17 |
| JP4544999B2 (ja) | 2010-09-15 |
| US20060040985A1 (en) | 2006-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE522502T1 (de) | Therapeutisches mittel gegen atemwegserkrankungen,das ein 4-hydroxypiperidinderivat als wirkstoff enthält | |
| PE20011348A1 (es) | Agentes antivirales de imidazopiridina e imidazopimiridina | |
| ATE402174T1 (de) | Imidazopyridinderivate als kinaseinhibitoren | |
| ATE475652T1 (de) | Chinazolinderivate | |
| NO20021401L (no) | Kinazolinforbindelser og farmasöytiske preparater som inneholder slike forbindelser | |
| ATE216584T1 (de) | Xanthine-derivate als antidepressiva | |
| ATE537830T1 (de) | Nicotinamid derivate und ihre verwendung als therapeutika | |
| ATE390415T1 (de) | Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung | |
| DE60324155D1 (de) | Indol-3-carbinol metaboliten als chemotherapeutische und chemopräventive wirkstoffen | |
| DE60236719D1 (de) | Purinderivate als antagonisten an purinergen rezeptoren | |
| DE60303954D1 (de) | Chinolyl-propylpiperidinderivate und deren verwendung als antimikrobielle wirkstoffe | |
| AR045959A1 (es) | Derivados de pirazolo- e imidazo-pirimidina | |
| NO20064297L (no) | Aminoalkoholforbindelse | |
| ATE300543T1 (de) | Kondensierte pyrazindionderivate als pde5 inhibitore | |
| BR0315777A (pt) | Uso de derivados de piperazina como antagonistas ccr1 | |
| KR970069990A (ko) | 페닐렌 유도체 | |
| NO20060146L (no) | Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav | |
| NO20064706L (no) | Thyroid reseptor agonister | |
| DE60202682D1 (de) | Chinoline derivate und ihre anwendung als antitumor agentien | |
| ATE170851T1 (de) | Guanidinothiazolederivate und ihre anwendung als h2-rezeptor-antagonisten | |
| ATE197458T1 (de) | Verbesserte antiandrogene | |
| AR021094A1 (es) | Compuestos heterociclicos inhibidores de la fosfodiesterasa iv y su uso para el tratamiento de enfermedades inflamatorias | |
| DE502004007387D1 (de) | Triazolverbindungen und ihre therapeutische verwendung | |
| ATE160566T1 (de) | Amphotere tricyclische verbindungen als antihistaminische und antiallergische mittel | |
| ATE238286T1 (de) | Neue triazole als therapeutische mittel gegen pilzinfektionen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |